TD Cowen Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Stacy Ku reaffirmed a Buy rating on Aurinia Pharmaceuticals (AUPH) with a $17.00 price target. Ku, a 4-star analyst in the Healthcare sector, maintains this stance alongside an overall Moderate Buy consensus for AUPH, which has a consensus price target of $15.67.
TD Cowen analyst Stacy Ku maintained a Buy rating on Aurinia Pharmaceuticals today and set a price target of $17.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Ku is a 4-star analyst with an average return of 13.3% and a 59.06% success rate. Ku covers the Healthcare sector, focusing on stocks such as Tonix Pharma, Protara Therapeutics, and Supernus Pharmaceuticals.
Aurinia Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $15.67.